Bringing the Oncology Community Together

No Survival Advantage for High-Dose Radiation Versus Standard-Dose Radiation in Stage III NSCLC

Alice Goodman
Published Online: Wednesday, January 11, 2012
Jeffrey D. Bradley, MD

Jeffrey D. Bradley, MD

High-dose radiation was no better than standard-dose radiation given concurrently with chemotherapy in extending survival of patients with advanced unresectable non-small cell lung cancer (NSCLC), according to interim results of a phase III trial. The results of the trial (RTOG 0617) were presented at the 2011 annual meeting of the American Society for Radiation Oncology (ASTRO) in Miami Beach, Florida. Overall survival was 74% in the high-dose group and 81% in the standard-dose group; median survival was 20 months versus 21.7 months, respectively.

“This was the first study in 30 years to see if a higher dose of radiation would have a survival benefit, and radiation techniques have improved significantly over that time,” said Jeffrey D. Bradley, MD, Washington University in St. Louis, Missouri. “There was no benefit for 74 Gy over 60 Gy, and the 74-Gy-dose arms were closed in June 2011. The 60-Gy dose should remain the accepted standard,” he stated.

The ongoing phase III trial plans to enroll 500 patients with stage III NSCLC; at the time of the interim analysis, enrollment was up to 423 patients. Patients were randomized to 4 arms: standard-dose radiation (60 Gy) plus chemotherapy (paclitaxel/ carboplatin) and cetuximab; standard-dose radiation with chemotherapy and no cetuximab; high-dose radiation (74 Gy) with chemotherapy plus cetuximab; and high-dose radiation with chemotherapy and no cetuximab. The second question the study is exploring is whether cetuximab provides added benefit over radiation and chemotherapy in this setting. That part of the trial is still open.

This was the first study in 30 years to see if a higher dose of radiation would have a survival benefit, and radiation techniques have improved significantly over that time. ”
–Jeffrey D. Bradley, MD
Baseline characteristics were similar among groups; more than 50% were men, and median age was 64 years. Median follow-up on the 423 enrolled patients is 9.1 months. After 90 events, the high-dose group crossed the futility boundary. Deaths have been due primarily to disease progression. Ten grade 5 treatment-related adverse events were reported; 8 on the high-dose arm and 5 on the standard-dose arm. Two deaths occurred from radiation pneumonitis in each arm. No significant difference in treatment-related toxicity was reported among the radiotherapy arms.

According to multivariate analysis, factors that contributed to worse survival were radiation dose, nonsquamous histology, and smaller tumor volume.

Speculating on why high-dose radiation did not improve survival, Bradley said that distant metastases pose a significant challenge in patients with lung cancer, and that radiation addresses local control, but not systemic control.

Related Articles
Next-Generation Targeted Therapies in NSCLC
In this segment, panelists discuss the number of early-phase clinical trials that have demonstrated impressive efficacy for next-generation ALK and EGFR inhibitors for patients with non-small cell lung cancer.
PD-L1 Predictive of Response to MK-3475 in Melanoma and NSCLC
PD-L1 levels adequately predict response and clinical outcomes for PD-1 inhibitor MK-3475 in patients with non-small cell lung cancer (NSCLC) and melanoma
Institute Develops Fresh Bench-to-Bedside Model Through Community Ties
In more than 40 years as a National Cancer Institute (NCI)-designated cancer center—and the first center in the network devoted purely to basic research—The Wistar Institute has built a reputation for furthering the sort of scientific research that will improve clinical cancer medicine.
MAGE-A3 Vaccine Falters in Large Phase III NSCLC Study
The large phase III MAGRIT study investigating the MAGE-A3-specific vaccine GSK1572932A for patients with non-small cell lung cancer (NSCLC) will be completely halted following an interim analysis that demonstrated a lack of benefit.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
OncLive Resources

OncLive TV
Oncology Nurses
Web Exclusives

About Us
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.